Verisante Technology, Inc. Announces 2013 Year End Results and Strategy for Direct Distribution

Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF) (the "Company" or
"Verisante"), a leader in cancer detection technology, announced today that the
Company has released its financial results for the year ended December 31, 2013.


Highlights of the year include:



--  First revenues from the sale of Aura(TM) recognized in 2013; 
--  Aura(TM) wins SPIE Prism Award for Photonics Innovation; 
--  Exhibiting at the World Congress of Dermatology in Hamburg; 
--  Completing phase 2 protoype of a Multispectral Imaging Camera; and 
--  Completion of the Core(TM) study for lung cancer and the start of a
    study on nasopharyngeal cancer using Core(TM).



Verisante continues to streamline its production and manufacturing facilities
and personnel to ensure the Company continues with the most cost-effective and
efficient path of commercialization. 


Revenues

Revenues are from the sale of Aura(TM) devices to the Company's exclusive
Distributors in Canada and Europe. The Company recognizes revenue when units are
shipped to the Distributor. For the year ending December 31, 2013 the Company
recognized revenue of $775,300 compared to $0 reported for the same period in
2012. 


The terms of sale of Aura(TM) devices are particular to the distribution
agreements signed with each exclusive Distributor in Canada and Europe.
Distributors have terms of sale which include shipping EXWorks the Company's
manufacturing warehouse and payment terms of net 30-90 days.


Expenses

Total expenses for the year ended December 31, 2013 was $5,179,540 in comparison
to $3,544,431 for the same period in 2012, representing an increase of
$1,635,109. Expenses for 2013 include non cash expenses of amortization of
$1,059,437 ($727,804 in 2012) and a bad debt expense of $508,262 ($0 in 2012).
The company expects total expenses to decrease as the Company consolidates
operations to preserve operating cash and focuses resources on sales and
marketing to support revenue generating operations. General and Administration
costs increased as a result of increased operations, from $1,982,832 in 2012 to
$2,980,387 in 2013, representing an increase of $997,555. 


As the Company began to recognize revenue in 2013, it also faced challenges in
collecting on accounts receivables from certain foreign customers. As a result a
bad debt expense of $508,262 was recognized in 2013 in comparison to $0 in 2012.
The Company is currently reviewing its payment policies in order to mitigate bad
debt risk in the future, which may require deposits from certain customers
before product is shipped.


The Company's full Year End Financials and MD&A can be found as filed at
www.sedar.com and also on the Company's website at www.verisante.com. 


Direct Distribution of Aura(TM) 

In late 2013 the Company began to pursue direct sales of Aura(TM) in Canada and
as a result made a strategic decision to not aggressively pursue its sales and
marketing strategy until such time as a trained and qualified direct sales team
was in place. 


Subsequent to the year end, the Company hired a Director of Sales and a Canadian
Sales Representative. Verisante's direct sales team believes the Company will be
ready for a full launch of its products (both Aura(TM) and the Company's Raman
Spectrometer for research purposes) in Q3 of 2014.


About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative
systems for the early detection of cancer. The Verisante Aura(TM) for skin
cancer detection and the Verisante Core(TM) series for lung, colon and cervical
cancer detection utilize a proprietary cancer detection platform while the
operating software and probe technology are unique to each device. The cancer
detection platform was developed by the BC Cancer Agency and tested and refined
at the Skin Care Centre at Vancouver General Hospital. This exclusive platform
technology allows Verisante to develop and offer a range of compact,
non-invasive cancer detection devices that offer physicians immediate results
for many of the most common cancers. Aura(TM) has been approved for sale in
Canada, Europe and Australia. Core(TM) has not yet been approved for sale. 


Verisante Aura(TM) was awarded Popular Science Magazine's "Best of What's New
Award" for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an
Edison Award for Excellence in Innovation in 2013. Verisante Core(TM) was named
one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. 


The TSX Venture Exchange has neither approved nor disapproved of the contents of
this press release. Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this press release. 


Website: www.verisante.com 

Youtube: www.youtube.com/verisante 

Twitter: www.twitter.com/verisante

Facebook: www.facebook.com/verisante

Forward-Looking Statements 

This release contains forward-looking statements, including, but not limited to,
statements regarding the future commercialization of medical devices, the market
demand for these products and the proprietary protections the Company will
obtain with regard to the technology, all of which statements are subject to
market risks, and the possibility that the Company will not be able to obtain
patent protection or obtain sufficient customer demand. These statements are
made based upon current expectations and actual results may differ from those
projected due to a number of risks and uncertainties.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Verisante Technology, Inc.
Thomas Braun
President & CEO
[phone]
[e-mail]
www.verisante.com